How can I evaluate endothelial damage in a high‑risk patient (hypertension, diabetes, smoker, dyslipidaemia) with possible microvascular disease?

Evaluating Endothelial Damage in High-Risk Patients

Flow-mediated dilation (FMD) of the brachial artery is the recommended non-invasive method to assess endothelial dysfunction in your high-risk patient with hypertension, diabetes, smoking, and dyslipidemia. 1, 2

Primary Assessment Method: Flow-Mediated Dilation (FMD)

FMD is the gold standard non-invasive ultrasound technique that directly measures endothelium-dependent vasodilation and predicts cardiovascular events in hypertensive patients. 1, 3

Technical Specifications for FMD Testing

• Perform high-resolution ultrasound of the brachial artery with measurement of arterial diameter changes following 5 minutes of forearm occlusion and subsequent reactive hyperemia 1, 4
• FMD values below 4.7% (the median threshold) indicate significant endothelial dysfunction and confer a 2.67-fold increased risk of cardiovascular events in hypertensive patients 3
• The test must be performed by qualified, experienced medical staff using standardized protocols to ensure reproducibility 2, 4

Clinical Significance in Your Patient Population

• In uncomplicated hypertensive patients, impaired FMD independently predicts nonfatal and fatal cardiovascular events even after controlling for age, sex, glycemia, cholesterol, smoking, BMI, blood pressure, and left ventricular mass 3
• Your patient with diabetes and dyslipidemia will likely show both impaired FMD (endothelium-dependent) and impaired nitroglycerin-mediated dilation (NED, endothelium-independent), as both mechanisms are compromised in diabetic patients with metabolic disturbances 1, 5
• The impaired FMD response correlates specifically with higher triglycerides and lower HDL-cholesterol in diabetic patients, making this test particularly relevant for your patient's lipid abnormalities 5

Complementary Vascular Assessment Methods

Carotid Intima-Media Thickness (IMT) and Plaque Detection

Duplex ultrasound of the carotid arteries with IMT measurement detects subclinical atherosclerosis and predicts both stroke and myocardial infarction independently of traditional risk factors. 1

• Measure IMT at the common carotid artery (reflecting vascular hypertrophy) and at carotid bifurcations (reflecting atherosclerosis) 1
• An IMT >0.9 mm indicates abnormality, though thresholds of 1.06-1.16 mm may be more appropriate for middle-aged patients 1
• Presence of plaque is defined as IMT ≥1.5 mm or focal increase of 0.5 mm or 50% above surrounding IMT 1
• Carotid ultrasound provides the greatest added predictive value in asymptomatic individuals at intermediate cardiovascular risk, which applies to your patient 1

Pulse Wave Velocity (PWV)

• Carotid-femoral PWV measures large artery stiffening, which is the primary determinant of isolated systolic hypertension 1
• This test is particularly relevant for your hypertensive patient but requires specialized equipment that may limit availability 1

Ankle-Brachial Index (ABI)

Measure ABI using continuous wave Doppler to detect peripheral artery disease, which signals advanced atherosclerosis and microvascular dysfunction. 1

• An ABI <0.9 indicates peripheral arterial disease and identifies patients at very high cardiovascular risk 1, 6
• This simple test provides robust information about systemic atherosclerotic burden 1

Microvascular-Specific Assessment

Microalbuminuria Screening

Screen for microalbuminuria in spot urine related to urinary creatinine excretion, as this is a routine procedure that detects microvascular dysfunction in hypertensive and diabetic patients. 1

• Microalbuminuria indicates derangement in the glomerular filtration barrier and predicts cardiovascular events 1
• In diabetic patients with microalbuminuria, both FMD and NED dilation are compromised, indicating more severe microvascular dysfunction 1
• This test is particularly critical for your patient with diabetes and hypertension 1

Estimated Glomerular Filtration Rate (eGFR)

• Calculate eGFR using the MDRD formula (requires age, gender, race, serum creatinine) to detect reduced renal function indicating microvascular damage 1
• Values <60 mL/min/1.73 m² indicate chronic kidney disease stage 3 and correlate with increased cardiovascular risk 1

Practical Testing Algorithm for Your Patient

1. First-line assessment: Perform FMD of the brachial artery to directly measure endothelial function 1, 2, 3
2. Concurrent microvascular screening: Obtain spot urine for microalbuminuria and calculate eGFR from serum creatinine 1
3. Atherosclerosis detection: Perform carotid duplex ultrasound with IMT measurement and plaque assessment 1
4. Peripheral vascular assessment: Measure ABI to detect systemic atherosclerotic burden 1

Critical Pitfalls to Avoid

• Do not rely solely on traditional risk factors without direct vascular assessment—endothelial dysfunction can be present even in patients without overt hypertension or microproteinuria 5
• Do not assume normal smooth muscle function if FMD is impaired—in diabetic patients with microalbuminuria, both endothelium-dependent (FMD) and endothelium-independent (NED) vasodilation are compromised 1
• Do not perform FMD without standardized protocols and experienced operators—the test has inherited confounding factors that must be controlled to ensure reproducibility 4
• Do not skip microalbuminuria screening—this should be routine in all hypertensive patients and those with metabolic syndrome, even with high-normal blood pressure 1

Response to Therapy Monitoring

• FMD improves with statin therapy in hypercholesterolemic patients and smokers, reflecting the pleiotropic effects of statins beyond lipid-lowering 1
• Metformin improves FMD in metabolic syndrome patients through reduction in insulin resistance 1
• Antihypertensive therapy effects on FMD are inconsistent—neither nifedipine nor captopril improved endothelial function in one study of hypertensive adults, though quinapril showed benefit in coronary artery disease patients 1